Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study
Judith Everts‐Graber, Stephan Reichenbach, Brigitta Gahl, H.R. Ziswiler, Ueli Studer, Thomas Lehmann
Topics & Concepts
DenosumabMedicineDiscontinuationOsteoporosisBone mineralInternal medicineHazard ratioUrologyOncologyConfidence intervalBone health and treatmentsBone health and osteoporosis researchBone Metabolism and Diseases